Olaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2Nh4vs1